ANI Pharmaceuticals | ANIP - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 9.39B 4.16B 2026-03
ANI Pharmaceuticals USD 311.18M 25.59M 2026-03
Aurora Cannabis CAD 56.36M 39.33M 2025-12
Canopy Growth CAD 371.32M 73.26M 2025-12
Eli Lilly USD 5.28B 1.99B 2026-03
Emergent BioSolutions USD 111.7M 23.9M 2023-12
Heron Therapeutics USD 26.12M 2.53M 2026-03
Hikma Pharmaceutical USD 236M 48M 2025-06
Knight Therapeutics CAD 76.45M 5.43M 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Novartis USD 9.56B 2.9B 2025-09
Omeros USD 1.9M 2.36M 2025-06
Perrigo USD 531.6M 99.5M 2025-12
Sun Pharmaceuticals INR 113.32B 33.19B 2025-03
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12